Dear Reader,
If you have any exposure to digital assets right now...
...read every word below.
.
.
.
Bitcoin dropped below $75,000.
For the first time since 2023, Michael Saylor's entire position went underwater.
His company, Strategy, holds 712,000+ BTC.
Average cost basis: $76,037.
At the low, he was sitting on $900 million in unrealized losses.
You know what he did?
He bought 855 more Bitcoin.
$75 million.
Now here's what makes this interesting...
While Saylor was buying...
358,000+ traders got liquidated.
$2.5 billion in leveraged positions... wiped out in 24 hours.
Retail panicked and sold at the worst possible moment. The largest corporate holder of Bitcoin on Earth... added to his position.
And he's not alone.
Glassnode data confirms mega-whales (wallets holding 10,000+ BTC) maintained accumulation the entire way down from $90,000 to $74,500.
They bought roughly 4X the weekly mining supply during the dip.
Meanwhile, BlackRock's Bitcoin ETF just recorded $142 million in inflows.
Fidelity added $153 million.
In a single day, $562 million flowed back into spot Bitcoin ETFs.
That's more than the entire month of January... in one session. While the Fear & Greed Index hit 14. "Extreme Fear."
And yet...
The people with the most information, the deepest pockets, and the longest time horizons are buying.
This is the pattern every single cycle.
March 2020. Bitcoin dropped 39%.
Retail fled.
Institutions loaded up.
Then it rallied 1,600% over the following year.
Inside Decentralized Masters, our members aren't guessing either… just like the financial institutions. They've become their own financial institution.
They're following a system and a research team with an 86.83% win rate across 539 tracked signals.
Third-party audited by a German wealth management firm regulated by BaFin.
When panic hits, they know exactly what to do.
I put together a free training that shows exactly how we position for moments like this.
✅ How we protect capital during drawdowns.
✅ How we identify what to accumulate when blood is in the streets.
✅ How our members could turn this crash into some of their best entries ever.
Watch this free training to see how this system works →
It's called the ABN System.
Three phases.
Phase A protects you. The same all-weather portfolio strategy BlackRock uses... applied to digital assets.
Phase B pays you. Passive income every single week. 10%, 20%, even 30%+ annually. Whether Bitcoin hits $150K or crashes to $30K.
Phase N multiplies you. Access to the private markets where assets trade BEFORE they hit Coinbase. Where our research team has an 86.83% win rate across 500+ tracked signals. Third-party audited.
Watch the free training here →
Talk soon,
Tan Gera, CFA
Co-Founder | Decentralized Masters
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Reported by Nathan Reiff. First Published: 2/2/2026.
In Brief
- Corvus Pharmaceuticals has nearly tripled in value this year amid optimism that its atopic dermatitis drug candidate will continue to deliver strong trial results.
- Despite legal and other hurdles, New Era Energy & Digital recently noted a key achievement in its path toward providing data center capacity.
- USA Rare Earth has received around $1.6 billion in federal funding as it seeks to provide a domestic alternative to foreign rare earth minerals.
Nearly one month into 2026, the S&P 500 has been sluggish, rising just over 1% after several dips in January. That middling performance, however, masks the fact that a number of individual companies have enjoyed a supercharged start to the year, dramatically outperforming the broader market.
Investors looking to capitalize on early momentum may consider Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), New Era Energy & Digital Inc. (NASDAQ: NUAI), and USA Rare Earth (NASDAQ: USAR) — each up at least 56% year-to-date (YTD).
Analysts Stay Bullish on Corvus With 50%+ Upside Targets
Executive Order 14330: Trump's Biggest Yet (Ad)
While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies...
Discover how to invest in the fund Trump uses to collect this income >>As a clinical-stage biopharma, Corvus operates in a sector prone to rapid, large stock swings. A recent catalyst has been positive Phase 1 data for soquelitinib, a candidate for treating atopic dermatitis and other conditions. In mid-January, Corvus reported Phase 1 results showing a 72% reduction in eczema severity among trial participants.
That news helped Corvus shares surge roughly 188% YTD. A Phase 2 trial is planned for early in the year and could further lift the stock. To fund the upcoming trial, Corvus launched a $150 million equity offering to extend its cash runway, though that move risks diluting existing shareholders. The financing is important given the company reported just $67 million in cash at the end of the third quarter of 2025.
Corvus is clearly banking on soquelitinib's continued success, and the addressable market for atopic dermatitis is sizable. Analysts remain optimistic: six of seven rate CRVS a Buy, and the consensus price target implies roughly 51% upside even after the recent rally (source).
New Era's Data Center Pivot Makes Big Strides, Though Legal and Other Risks Remain
New Era & Digital is one of the more polarizing names among energy exploration and production companies. Shares of NUAI are up more than 114% YTD after the firm announced a partnership with Primary Digital Infrastructure to deliver up to a gigawatt of data center capacity to hyperscalers — a key step in its pivot toward the high-demand data center market. Earlier in the month, New Era also closed the acquisition of the remaining 50% interest in Texas Critical Data Centers, further positioning the company for its new focus.
Those moves suggest New Era could succeed in its ambitious reorganization. Yet the company faces legal scrutiny: the Rosen Law Firm has announced an investigation into allegations of "materially misleading business information." With a market value just under $400 million, New Era remains a high-risk investment; investors who can tolerate that risk may be rewarded if the rally continues.
USA Rare Earth Looks to Fill a Significant Supply Chain Need With Government Support
Rare-earth minerals are increasingly critical to many technologies, and supply-chain concerns risk bottlenecking U.S. supplies. USA Rare Earth aims to provide a domestic alternative. The company has been buoyed by a $1.6 billion investment — including federal support — and additional private funding in recent weeks, along with a strong cash position reported with its latest earnings (source).
Its rare-earth and magnet production capacity is expanding rapidly from key operations in Texas, and revenues are expected to grow substantially. That said, USA Rare Earth is still an early-stage company without a proven track record of profitability, which may deter some investors. Still, a 56% YTD gain and a strongly optimistic analyst profile point to significant upside potential.
These three names illustrate how individual stocks can vastly outpace the broader index early in 2026. Investors attracted to that upside should weigh it against the elevated risks — from trial outcomes and dilution at Corvus to legal and execution risks at New Era, and early-stage operational risk at USA Rare Earth.
This message is a sponsored email from Decentralized Masters, a third-party advertiser of MarketBeat. Why was I sent this email content?.
If you need assistance with your newsletter, please don't hesitate to email our U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Suite 620, Sioux Falls, South Dakota 57103. United States..
No comments:
Post a Comment